Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Heeger, CH; Almorad, A; Scherr, D; Szegedi, N; Seidl, S; Baran, J; Duytschaever, M; Gupta, D; Linz, D; Lyan, E; Rocca, DD; Gellér, L; Knecht, S; Calvert, P; Meilak, S; Leventopoulos, G; Popescu, SS; Rauber, M; Kollias, G; Niedzwiedz, M; Sarkozy, A; Badoz, M; Manninger-Wünscher, M; Sciacca, V; Sohns, C; Ginks, MR; Pürerfellner, H; Tilz, RR.
Temperature-guided high and very high-power short duration ablation for atrial fibrillation treatment: the peQasus multicentre study.
Europace. 2025; 27(6): Doi: 10.1093/europace/euae284 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz
Scherr Daniel
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
AIMS: Temperature-controlled high-power short-duration (HPSD) radiofrequency catheter ablation for pulmonary vein isolation (PVI) utilizing a novel ablation catheter (QDOT Micro) with real-time assessment of catheter tip temperature aims for safer, more effective, and faster procedures. METHODS AND RESULTS: The peQasus study is a large European multicentre study set up to assess safety, acute efficacy, and outcomes of temperature-controlled HPSD-based PVI. The primary endpoints were safety, efficacy, and 12-month freedom from atrial tachyarrhythmias. Additionally, two strategies namely very HPSD (90 W for 4 s) only and a hybrid approach (HPSD with maximum of 50 W and vHPSD) were compared. A total of 1023 AF patients in 15 centres from nine European countries received PVI with the QDOT. Complete PVI was successfully achieved in all patients. In 699/1023 (68.3%), the vHPSD-only approach (vHPSD group) and in 324/ (31.7%) patients, the hybrid approach (hybrid group) was utilized. The mean procedure duration was 98.4 ± 37.4 min (vHPSD: 88.2 ± 34.9 min, hybrid: 117.4 ± 32.7 min, P < 0.001). The first-pass isolation rate of all PVs was 64% (vHPSD: 62.6%, hybrid: 67.1%, P = 0.187). Severe adverse events were observed in 1.7% (vHPSD: 1.6%, hybrid: 1.9%, P = 0.746). Twelve-month arrhythmia-recurrence-free survival was 77.1% (vHPSD: 76.8%, hybrid: 77.8%, P = 0.241). CONCLUSION: In this large multicentre study, temperature-controlled HPSD and vHPSD ablation via a novel ablation catheter provides safe and effective PVI with a relatively short procedure duration. Despite a shorter procedure time, no differences in terms of safety and freedom from arrhythmia recurrence were found irrespective of utilizing vHPSD or the hybrid approach.
Find related publications in this database (using NLM MeSH Indexing)
Humans - administration & dosage
Atrial Fibrillation - surgery, physiopathology, diagnosis
Male - administration & dosage
Female - administration & dosage
Catheter Ablation - adverse effects, instrumentation, methods
Middle Aged - administration & dosage
Pulmonary Veins - surgery, physiopathology
Europe - administration & dosage
Aged - administration & dosage
Recurrence - administration & dosage
Time Factors - administration & dosage
Treatment Outcome - administration & dosage
Cardiac Catheters - administration & dosage
Equipment Design - administration & dosage
Action Potentials - administration & dosage
Operative Time - administration & dosage
Temperature - administration & dosage
Heart Rate - administration & dosage

Find related publications in this database (Keywords)
Atrial fibrillation
High-power short duration
Pulmonary vein isolation
Radiofrequency
Acute efficacy
© Med Uni Graz • Impressum